ReviewDialogues in clinical neuroscience2020
Cannabinoids and their therapeutic applications in mental disorders .
Review in Dialogues in clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Advances in targeted liquid chromatography-tandem mass spectrometry methods for endocannabinoid and N-acylethanolamine quantification in biological matrices: A systematic review.Mass spectrometry reviewsPooled it
- Chronic Δ9-Tetrahydrocannabinol Inhalation Following Osteoporosis Results in Bone Deficits.Biomedicines · 2026Article
- Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.Translational psychiatry · 2026Review
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Epidemiology of Cannabis Use Among Middle-Aged and Older Adults in the U.S.American journal of preventive medicine · 2026Article
- Violence Exposure Relates Differently to Blood Pressure and Emotional Health as a Function of Cannabis Use Among Street-Identified Black Americans.Clinical psychological science : a journal of the Association for Psychological Science · 2025Article
- From farm to bedside: Potential of medical cannabis in global health.Complementary therapies in medicine · 2025Review
- Medical Cannabis and Psychological Well-Being in Illinois' Opioid Alternative Pilot Program.American journal of preventive medicine · 2025Article
- Exposotypes in psychotic disorders.Scientific reports · 2025Article
- Chronic Disease Symptoms Self-Managed by Cannabis During the COVID-19 Pandemic: Results from the COVID-19 Cannabis Health Study.Cannabis and cannabinoid research · 2025Article
- Alcohol and cannabis use for pain management: Translational findings of relative risks, benefits, and interactions.Physiology & behavior · 2025Review
- Patient-provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study.The American journal on addictions · 2025Article
- CANDI: a web server for predicting molecular targets and pathways of cannabis-based therapeutics.Journal of cannabis research · 2025Article
- Prevalence of cannabidiol use and correlates in U.S. adults.Drug and alcohol dependence reports · 2024Article
- CANDI: A Web Server for Predicting Molecular Targets and Pathways of Cannabis-Based Therapeutics.Research square · 2024Article
- Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19-A Scoping Review.Journal of clinical medicine · 2023Article
- Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.Frontiers in pharmacology · 2023Article
- Exploration of Multiverse Activities of Endocannabinoids in Biological Systems.International journal of molecular sciences · 2022Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.